The Tecan Group announced that Dr. Klaus Lun, Head of Corporate Development and a member of the Management Board of the Tecan Group since June 2013, has been appointed Head of the Life Sciences Business division. On December 14, 2016, Tecan announced that Dr. Stefan Traeger, Head of the Lif ... more
Tecan and Enigma Diagnostics sign global manufacturing and supply agreement for point-of-care Molecular Diagnostics instruments
The Tecan Group and Enigma Diagnostics Limited announced the signing of a manufacturing and supply agreement for Enigma's ML instruments. Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma's global market supplies for an initial five-year contract and will also manage the ML instrument's supply chain. Financial details of the agreement were not disclosed.
John McKinley, Chairman and CEO of Enigma, said: "This is a milestone agreement for Enigma. We chose Tecan for its leading reputation as a developer and manufacturer of commercial medical instruments and its global range of technical and support services network. This represents the first of a number of potential additional agreements relating to Tecan's support of the Enigma ML system."
- Enigma Diagnostics
- molecular diagnostics
The Tecan Group announced the acquisition of US-based SPEware Corporation (SPEware) to further expand Tecan's dedicated solutions offering into a new market segment. SPEware is a leading provider for mass spectrometry sample preparation solutions, with a focus on the North American market. ... more
Tecan announced the results of the Tecan Award 2011. The award has been won by Svenja Kristina Holle from the University Hospital of Muenster (UHM), Germany. Using an Infinite® 200 microplate reader, Svenja and the UHM team have developed an ex vivo method for investigating the dynamics of ... more
The Tecan Group and Enigma Diagnostics Limited announced the signing of a manufacturing and supply agreement for Enigma's ML instruments. Under the agreement, Tecan will industrialize and deliver commercially manufactured ML instruments for Enigma's global market supplies for an initial fiv ... more
Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced four senior appointments for its US and European offices. Dr. Jorge Garces will lead the US team as President and CEO with Greg Hamilton, Chief Operating Officer and Chief Financial Off ... more
Enigma Diagnostics Limited announced that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS). The licenses signed on15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemis ... more
- 1Potential cause for lupus identified
- 2Why do BRCA1 mutations cause predominantly breast and ovarian cancer?
- 3Peptide complex formed in the brain is responsible for Alzheimer's disease
- 4LUM incorporates subsidiary in the Land of the rising sun
- 5Personalize your medication dosages
- 6The proton precisely weighted
- Enterome and Nestlé Health Science launch new diagnostics company
- MRC Technology and Biocartis initiate development of liquid biopsy test for ...
- DKSH extends partnership with LAUDA to Singapore and Taiwan
- Prestigious grant for imaging single molecules
- QIAGEN joins CANCER-ID consortium for liquid biopsy workflows